724 Original Article Identification genes pathways leading poor prognosis nonsmall cell lung cancer integrated bioinformatics analysis Shengjin Cui1 Shuang Lou1 Jingying Feng1 Xi Tang1 Xiaowei Xiao1 Rong Huang1 Weiquan Guo1 Yiwen Zhou1 Feixia Huang2 1Department Clinical Laboratory Shenzhen Hospital Southern Medical University Shenzhen China 2Department Traditional Chinese Medicine The University Hong KongShenzhen Hospital Shenzhen China Contributions I Conception design S Cui F Huang II Administrative support Y Zhou F Huang III Provision study materials patients S Cui R Huang IV Collection assembly data S Lou J Feng V Data analysis interpretation W Guo X Xiao VI Manuscript writing All authors VII Final approval manuscript All authors Correspondence Yiwen Zhou Department Clinical Laboratory Shenzhen Hospital Southern Medical University No 1333 Xinhu Road Shenzhen 518110 China Email yiwenzhou21aliyuncom Feixia Huang Department Traditional Chinese Medicine The University Hong KongShenzhen Hospital Haiyuan Road Shenzhen 518053 China Email shirenyirui163com Background Nonsmall cell lung cancer NSCLC common malignancy high morbidity mortality rate worldwide driver genes signaling pathways involved largely unclear Herein study aimed identify significant genes poor outcome underlying mechanisms NSCLC bioinformatics analyses Methods Gene expression profiles GSE33532 GSE19188 GSE102287 GSE27262 including 319 NSCLC 232 adjacent lung tissues downloaded GEO database Differentially expressed genes DEGs identified GEO2R online tool Functional pathway enrichment analyses performed DAVID database The proteinprotein interactions PPIs DEGs constructed STRING website visualized Cytoscape software platform The expression hub genes NSCLC validated GEPIA database KaplanMeier plotter analyse survival rate multivariate Cox regression The expression protein tyrosine kinase 2 PTK2 NSCLC adjacent lung tissues evaluated UALCAN database platform Results A total 225 significant DEGs obtained NSCLC adjacent lung tissues containing 52 upregulated genes 173 downregulated genes The DEGs clustered based functions signaling pathways closely associated NSCLC occurrence A total 174 DEGs identified PPI network complex Top 10 hub genes selected CytoHubba plugin As independent predictors seven genes COL1A1 ADAM12 VWF OGN EDN1 CAV1 ITGA8 associated poor prognosis NSCLC multivariate Cox regression P001 Four genes VWF CAV1 ITGA8 COL1A1 significantly enriched focal adhesion pathway P104E04 upstream regulators PTK2 PTK2 upregulated NSCLC associated poor survival prognosis lung squamous cell carcinoma LUSC Conclusions Taken important genes pathways NSCLC identified integrated bioinformatics analysis PTK2 key gene associated biological process NSCLC formation progression potential therapeutic target NSCLC treatment Keywords Nonsmall cell lung cancer NSCLC bioinformatics differentially expressed genes DEGs Submitted Sep 17 2021 Accepted publication Feb 17 2022 doi 1021037tcr211986 View article httpsdxdoiorg1021037tcr211986 Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 Translational Cancer Research Vol 11 No 4 April 2022 711 Introduction Lung cancer common malignancies world 1 Lung cancer classified nonsmall cell lung cancer NSCLC small cell lung cancer SCLC NSCLC significantly common SCLC subdivided based histology adenocarcinoma squamous large cell carcinoma 23 Despite introduction new effective biomarkers clinical practice 25 NSCLC patients diagnosed stage III NSCLC patients amenable radical surgery 4 The 5year survival 7792 clinical stage IA 68 stage IB 60 stage IIA 53 stage IIB 5 Radical surgery improved 5year survival rates patients stage III NSCLC However NSCLC patients diagnosed late stage typically asymptomatic early stage lack effective screening trial These patients advanced NSCLC amenable radical surgery 69 potentially actionable molecular target 6 Epidermal growth factor receptor EGFR anaplastic lymphoma kinase ALK common oncogenic drivers NSCLC Although EGFR tyrosine kinase inhibitor TKI ALK TKI treatment encouraging improvement overall survival nearly patients eventually disease progression acquired resistance treatment 7 The reduction NSCLC mortality set major priority worldwide detecting new molecular targets prompting development new therapies Traditional genebygene approaches research insufficient meet growth demand biological research understanding true biology In recent years bioinformatics analysis identified group cancer related genes provide insight molecular mechanism diseases progression 89 Nevertheless studies NSCLC bioinformatics analyses In paper bioinformatics analysis utilized explore potential biomarkers molecular mechanism NSCLC We present following article accordance REMARK reporting checklist available httpstcr amegroupscomarticleview1021037tcr211986rc Methods In paper original microarray datasets downloaded GEO DEGs NSCLC adjacent lung tissue filtered GEO2R online tool The functions pathway enrichment differentially expressed genes DEGs identified DAVID online database The proteinprotein interactions PPIs DEGs constructed STRING website visualized Cytoscape software platform The GEPIA database evaluate expression genes KaplanMeier plotter analyse survival rate multivariate Cox regression The expression protein tyrosine kinase 2 PTK2 analysed UALCAN database All procedures performed study involving human participants accordance Declaration Helsinki revised 2013 Microarray data information DEGs identification NCBIGEO httpswwwncbinlmnihgovgds functional genomics database includes microarray cutting edge sequencing Four original microarray datasets GSE33532 GSE19188 GSE102287 GSE27262 downloaded NCBIGEO database data 319 NSCLC 232 adjacent lung tissues available DEGs NSCLC adjacent lung tissue filtered GEO2R online tool P005 logFC 2 10 The overlapping DEGs datasets identified Venn diagram database httpbioinformaticspsbugentbewebtoolsVenn The DEGs logFC 0 upregulated genes contrast gene downregulated gene logFC 0 Gene functional pathways enrichment analysis Gene ontology GO comprises 3 independent ontologies cellular component molecular function biological process comprehensive widely knowledge base concerning functions genes 11 Kyoto Encyclopedia Genes Genomes KEGG database resource understanding highlevel functions utilities biological systems 12 DAVID httpsdavidncifcrfgovhomejsp comprehensive functional annotation tool investigators understand biological meaning large list genes 13 In present study functions pathway enrichment DEGs identified DAVID online database P005 cutoff criterion Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 712 Cui et al Identification important genes pathways NSCLC Table 1 A total 225 common DEGs 52 upregulated genes 173 downregulated genes detected 4 profile datasets DEG Gene symbol Upregulated Downregulated ADAM12 TPX2 CCNB1 SULF1 HMGB3 ASPM FERMT1 HMMR CXCL13 KIF4A GINS1 TMPRSS4 HS6ST2 SPP1 COL1A1 ADAMDEC1 ANLN BIRC5 KIF20A UBE2C COL10A1 CCNB2 PSAT1 TYMS CDCA7 MELK COL11A1 KIF11 CEP55 CDC20 CTHRC1 RRM2 ZWINT TOP2A KIAA0101 GJB2 GREM1 TTK GTSE1 CDKN3 BUB1 NUF2 CENPU MMP1 NEK2 MMP12 AURKA UBE2T CENPF TFAP2A MAD2L1 DLGAP5 HBA2HBA1 EDN1 RTKN2 EMCN SOX7 ADARB1 CHRDL1 PPP1R14A ADGRD1 GPIHBP1 KCNT2 MFAP4 PEBP4 ITIH5 ERG SLC6A4 PECAM1 KCNK3 MMRN2 NOSTRIN SYNPO2 NCKAP5 GIMAP8 OGN SCARA5 BTNL9 PCAT19 IGSF10 ACVRL1 SCGB1A1 CDO1 CA4 SDPR WWC2CLDN22 TEK CLIC3 GRK5 ID4 EXOSC7CLEC3B PLA2G1B DACH1 VGLL3 FAM150B ANOS1 ACKR1 LIFR STXBP6 S1PR1 EMP2 LYVE1 ADAMTS8 HBEGF PTPN21 GDF10 LAMP3 LIMCH1 LEPROTLEPR DNASE1L3 BCHE SPOCK2 AKAP12 CD36 FAM162B PDE5A LDB2 ROBO4 SPTBN1 CALCRL CAV1 TBX5AS1 PPBP JAM2 PTPRB QKI FOXF1 ACADL ANKRD29 PIRFIGFFIGF AQP4 NEBL ITGA8 MT1M TNNC1 PDZD2 FAT3 ADIRF MCEMP1 HBB FHL1 RHOJ CPB2 SRPX FAM189A2 SORBS2 LRRN3 THBD KLF4 EMP1 FMO2 ABCA8 MYZAP SOCS2 SLC39A8 AOC3 SFTPC ADRB1 SEMA3G TCF21 NEDD4L TGFBR3 HHIP PGC ADH1B ARHGEF26 ARHGAP6 LPL ASPA FABP4 EDNRB SOSTDC1 SCN4B FCN3 MYCT1 KANK3 DLC1 STX11 LINC00312 FAM107A CCDC85A PLAC9 CCBE1 PGM5 C1QTNF7 GPX3 AGER FOSB RGCC VWF SEMA5A PIP5K1B ABI3BP CD93 BMP2 TIE1 KIAA1462 VIPR1 AGTR1 WIF1 EPAS1 RAMP3 CLIC5 NPNT SLIT2 GIMAP6 FHL5 MAMDC2 ADAMTSL3 CLDN18 C2orf40 CDH5 PDK4 GPM6A COL6A6 FILIP1 CFD GKN2 ANGPT1 CYP4B1 SMAD6 HYAL1 TMEM100 DUOX1 AFF3 DEG differentially expressed gene PPI network module analysis The PPI network proteins encoded DEGs constructed STRING database httpscnstring dborg 14 The Cytoscape software platform https cytoscapeorg utilized construct visualize PPI network maximum number inter actors 0 confidence score 04 15 The nodes represent genes edges nodes represent interactions genes PPI network Expression survival analysis hub genes NSCLC The expression hub genes NSCLC adjacent lung tissues compared GEPIA database httpgepiacancerpkucn 16 NSCLC patients divided low highexpression groups according median expression hub gene KaplanMeier analysis performed KaplanMeier plotter https kmplotcomanalysis 17 P value includes correction multiple hypothesis testing P005 indicated difference statistically significant Expression survival analysis PTK2 NSCLC The UALCAN database httpualcanpathuabedu employed analyse expression PTK2 NSCLC adjacent lung tissues 18 The survival prognosis PTK2 evaluated KaplanMeier plotter Statistical analysis Bioinformatics analyses databases described method The twosided Students ttest compare differences groups Differences groups compared sided Students ttest KaplanMeier analysis performed KaplanMeier plotter P005 considered statistically significant Results Microarray data information DEGs identification Four original microarray datasets GSE33532 GSE19188 GSE102287 GSE27262 obtained NCBIGEO database A total 3188 DEGs extracted GEO2R online tool P005 logFC 2 cutoff criteria A total 225 common DEGs identified Venn diagram database including 52 upregulated genes 173 downregulated genes NSCLC tissue compared adjacent lung tissues Table 1 Figure 1 Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 Translational Cancer Research Vol 11 No 4 April 2022 713 A GSE19188 GSE27262 B GSE19188 GSE27262 S E 3 3 5 3 2 G 35 24 20 4 2 11 52 51 7 8 5 10 30 35 G S E 1 0 2 2 8 7 S E 3 3 5 3 2 G 46 94 41 50 6 11 30 13 G S E 1 0 2 2 8 7 37 162 3 173 1111 56 46 38 Figure 1 Venn diagram GSE33532 GSE19188 GSE102287 GSE27262 datasets A 52 upregulated genes overlapped profile datasets B 173 downregulated genes overlapped profile datasets Gene function pathways enrichment analysis PPI network module analysis Functions pathway enrichment DEGs conducted DAVID database The DEGs classified functional groups biological process group BP cellular component group CC molecular function group MF Figure 2 Table 2 In BP group cell division GO term enriched upregulated downregulated DEGs indicates biological process cell division play vital roles development NSCLC In addition upregulated DEGs involved mitotic nuclear division sister chromatid cohesion downregulated DEGs involved angiogenesis BMP signaling pathway In CC group upregulated DEGs enriched spindle midbody condensed chromosome kinetochore downregulated DEGs enriched cell surface extracellular region extracellular space In MF group overexpressed DEGs mainly included molecular functions ATP binding metalloendopeptidase activity protein homodimerization activity downregulated genes included heparin binding receptor activity transforming growth factor beta binding As shown Table 3 KEGG analysis results demonstrated upregulated DEGs significantly enriched oocyte meiosis cell cycle p53 signaling pathway downregulated DEGs particularly enriched malaria vascular smooth muscle contraction PPAR signaling pathway A total 174 DEGs including 48 upregulated genes 126 downregulated genes filtered PPI network complex included 174 nodes 816 edges STRING database Cytoscape software platform Figure 3A There 51 225 DEGs failed fall PPI network Two significant modules PPI network complex collected analysis MCODE plugin Cytotype software platform A total 32 central nodes 511 edges identified module 1 32 central nodes upregulated genes mainly associated oocyte meiosis cell cycle p53 signaling pathway progesteronemediated oocyte maturation Figure 3B Table 4 In addition module 2 included 9 nodes 29 edges mainly associated PI3KAkt HIF1 signaling pathways Figure 3C Table 4 The CytoHubba plugin identify 10 hub genes COL1A1 ITGA8 VWF MMP1 ADAM12 CD36 OGN EDN1 CTHRC1 CAV PPI network Figure 3D Table 4 mainly involved ECM receptor interaction focal adhesion PI3KAkt signaling pathway Expression survival analysis hub genes NSCLC The GEPIA database utilized analyse expression 10 hub genes NSCLC adjacent lung tissues COL1A1 MMP1 ADAM12 CTHRC1 Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 714 Cui et al Identification important genes pathways NSCLC A s e n e g t e g r T B s e n e g t e g r T 30 25 20 15 10 5 0 50 40 30 20 10 0 Figure 2 GO analysis DEGs NSCLC A GO analysis upregulated DEGs B GO analysis downregulated DEGs GO gene ontology DEGs differentially expressed genes NSCLC nonsmall cell lung cancer Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 Translational Cancer Research Vol 11 No 4 April 2022 715 Table 2 GO analysis differentially expressed genes NSCLC Expression Category Term Count Upregulated GOTERM_BP_DIRECT GO0051301 GOTERM_BP_DIRECT GO0007067 cell division GOTERM_BP_DIRECT GO0007062 mitotic nuclear division sister chromatid cohesion GOTERM_BP_DIRECT GO0000086 G2M transition mitotic cell cycle GOTERM_BP_DIRECT GO0007051 spindle organization GOTERM_BP_DIRECT GO0007094 mitotic spindle assembly checkpoint GOTERM_CC_DIRECT GO0005819 spindle GOTERM_CC_DIRECT GO0030496 midbody GOTERM_CC_DIRECT GO0000777 condensed chromosome kinetochore 15 13 8 8 4 4 8 8 7 1704 P value FDR 145E12 207E09 1477 787E12 112E08 909 247E08 352E05 909 177E07 252E04 454 144E05 002049 454 290E05 004136 909 434E08 477E05 909 676E08 743E05 795 151E07 166E04 GOTERM_CC_DIRECT GO0005654 24 2727 390E07 428E04 nucleoplasm GOTERM_CC_DIRECT GO0000922 spindle pole GOTERM_CC_DIRECT GO0000776 kinetochore 7 6 795 577E07 634E04 682 306E06 000337 GOTERM_MF_DIRECT GO0005524 12 1363 000316 356706 GOTERM_MF_DIRECT GO0004222 ATP binding metalloendopeptidase activity GOTERM_MF_DIRECT GO0042803 4 7 protein homodimerization activity 454 000430 482813 795 001842 1921940 Table 2 continued Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 716 Table 2 continued Cui et al Identification important genes pathways NSCLC Expression Category Term Count Downregulated GOTERM_BP_DIRECT GO0001525 angiogenesis GOTERM_BP_DIRECT GO0007155 GOTERM_BP_DIRECT GO0030509 cell adhesion BMP signaling pathway GOTERM_BP_DIRECT GO0042310 GOTERM_BP_DIRECT GO0051591 vasoconstriction GOTERM_BP_DIRECT GO0001666 response cAMP response hypoxia GOTERM_CC_DIRECT GO0009986 cell surface GOTERM_CC_DIRECT GO0005576 extracellular region GOTERM_CC_DIRECT GO0005615 GOTERM_CC_DIRECT GO0005578 extracellular space proteinaceous extracellular matrix GOTERM_CC_DIRECT GO0045121 membrane raft GOTERM_MF_DIRECT GO0008201 GOTERM_MF_DIRECT GO0004872 heparin binding GOTERM_MF_DIRECT GO0050431 receptor activity transforming growth factor beta binding 14 18 7 4 5 8 20 34 29 12 10 9 8 3 537 P value FDR 886E08 144E04 691 624E07 000101 269 557E05 009039 154 417E04 067403 192 709E04 114466 307 834E04 134494 768 272E07 330E04 1305 285E06 000345 1113 143E05 001737 461 240E05 002907 384 831E05 010057 345 511E05 006988 307 000206 277954 115 000739 963795 GO gene ontology NSCLC nonsmall cell lung cancer FDR false discovery rate BMP bone morphogenetic protein Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 Translational Cancer Research Vol 11 No 4 April 2022 717 Table 3 KEGG pathway enrichment analysis differentially expressed genes NSCLC Expression Pathway ID Name Count Upregulated hsa04114 Oocyte meiosis hsa04110 Cell cycle hsa04115 p53 signaling pathway hsa04914 Progesteronemediated oocyte maturation hsa04512 ECMreceptor interaction hsa04974 Protein digestion absorption Downregulated hsa05144 Malaria hsa04270 Vascular smooth muscle contraction hsa03320 PPAR signaling pathway hsa04610 Complement coagulation cascades hsa04514 CAMs 6 6 4 4 4 3 4 5 4 4 5 682 P value 211E05 682 362E05 Genes CCNB1 MAD2L1 CCNB2 BUB1 AURKA CDC20 CCNB1 MAD2L1 CCNB2 BUB1 TTK CDC20 455 455 455 341 154 192 154 154 000119 CCNB1 CCNB2 RRM2 GTSE1 000253 CCNB1 MAD2L1 CCNB2 BUB1 000253 COL1A1 COL11A1 SPP1 HMMR 003166 COL1A1 COL11A1 COL10A1 001182 002681 002717 002931 CD36 PECAM1 ACKR1 HBB RAMP3 AGTR1 PLA2G1B CALCRL PPP1R14A LPL CD36 FABP4 ACADL VWF THBD CFD CPB2 192 004910 CLDN18 ITGA8 PECAM1 JAM2 CDH5 KEGG Kyoto Encyclopedia Genes Genomes NSCLC nonsmall cell lung cancer ECM extracellular matrix PDAR peroxisome proliferatoractivated receptor CAMs cell adhesion molecules significantly upregulated P005 VWF CD36 OGN EDN1 CAV1 ITGA8 significantly downregulated P005 NSCLC Figure 4A Survival curves generated assess diagnostic efficiency 10 hub genes KaplanMeier plotter As shown Figure 4B upregulated genes COL1A1 ADAM12 downregulated genes VWF OGN EDN1 CAV1 ITGA8 significantly associated survival prognosis NSCLC P001 Reanalysis hub genes KEGG enrichment analysis KEGG enrichment analysis reanalyzed explore possible pathways 7 hub genes DAVID database Four genes VWF CAV1 ITGA8 COL1A1 markedly enriched focal adhesion pathway P104E04 upstream regulators FAK PTK2 Table 5 Expression survival analysis PTK2 NSCLC The expression PTK2 NSCLC adjacent lung tissues analysed UALCAN database Compared adjacent lung tissues PTK2 significantly overexpressed lung adenocarcinoma LUAD lung squamous cell carcinoma LUSC P001 Figure 5A5B PTK2 associated poor prognosis LUSC HR 143 P005 Figure 5C LUAD HR 069 P005 Figure 5D Discussion NSCLC common malignant cancer fourth lowest survival rate cancer types worldwide 19 Although numerous basic clinical studies conducted reveal causes underlying mechanisms NSCLC formation progression gene mechanism gene expression NSCLC systematically studied This study utilized bioinformatics methods deeply analyse profile datasets downloaded GEO database A total 225 DEGs obtained DAVID online database classified groups MF BP CC groups GO terms The cell division Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 Cui et al Identification important genes pathways NSCLC 718 A C B D Figure 3 The PPI network DEGs 10 hub genes A The PPI network consisted 174 nodes 816 edges 48 upregulated genes marked red 126 downregulated genes marked green B module 1 composed 32 nodes 511 edges C module 2 composed 9 nodes 29 edges D 10 hub genes identified cytoHubba plugin PPI proteinprotein interaction DEGs differentially expressed genes GO term enriched upregulated downregulated DEGs indicates biological process cell division play vital roles development NSCLC For pathway analysis upregulated DEGs particularly enriched oocyte meiosis cell cycle p53 signaling pathway downregulated DEGs enriched malaria vascular smooth muscle contraction PPAR signaling pathway P005 As tumor inhibitor p53 plays pivotal role cell biological functions cell cycle progression DNA damage response apoptosis senescence angiogenesis 20 Tac2N TC2N acts novel oncogene inhibiting apoptosis promoting proliferation lung cancer cells inhibiting p53 signaling pathway 21 On basis CytoHubba plugin Cytoscape software platform 10 hub genes identified mainly involved ECMreceptor interaction focal adhesion PI3KAkt signaling pathway Four Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 Translational Cancer Research Vol 11 No 4 April 2022 719 Table 4 KEGG pathway analysis module 1 module 2 genes Module Pathway ID Name Count P value Genes Module 1 hsa04114 Oocyte meiosis pathway hsa04110 Cell cycle hsa04115 p53 signaling pathway hsa04914 Progesteronemediated oocyte maturation pathway Module 2 hsa04151 PI3KAkt signaling pathway hsa04066 HIF1 signaling pathway Hubba Top 10 hsa04512 ECMreceptor interaction pathway hsa04510 Focal adhesion pathway hsa04151 PI3KAkt signaling pathway KEGG Kyoto Encyclopedia Genes Genomes 6 6 4 4 4 3 4 4 3 1043 116E06 1043 201E06 CCNB1 MAD2L1 CCNB2 BUB1 AURKA CDC20 CCNB1 MAD2L1 CCNB2 BUB1 TTK CDC20 695 695 2582 1937 40 40 30 236E04 CCNB1 CCNB2 RRM2 GTSE1 510E04 CCNB1 MAD2L1 CCNB2 BUB1 000223 000279 VWF TEK ANGPT1 SPP1 EDN1 TEK ANGPT1 380E05 VWF CD36 ITGA8 COL1A1 495E04 VWF CAV1 ITGA8 COL1A1 003289 VWF ITGA8 COL1A1 10 genes enriched focal adhesion pathway upstream regulators FAK PTK2 including VWF CAV1 ITGA8 COL1A1 The integrin activated adhesion kinase FAKmediated signaling pathway important pathway tumor invasion metastasis 22 PTK2 adhesion protein kinase plays important role FAKmediated signaling pathway includes transduction signals released integrins growth factor receptors 2325 In present study PTK2 expression significantly higher NSCLC adjacent lung tissues Moreover PTK2 overexpression associated poor survival LUSC correlation LUAD As study multiple studies demonstrated PTK2 overexpressed andor activated tumor types including NSCLC 2630 It previously reported PTK2 overexpression evaluated IHC correlated worse overall survival 3132 These data illustrate PTK2 play important role tumour formation progression Therefore smallmolecule inhibitors targeting PTK2 kinase domain undergoing preclinical clinical investigation induce cancer regression solid cancers including NSCLC 3337 As robust inhibition PTK2 PF562 271 provides potential enhance cancer therapy novel target dual antitumor antiangiogenesis mechanisms action represents unprecedented p p r o c h t o N S C L C t r e t m e n t t h r o u g h P T K 2 inhibition 38 Conclusions In summary 225 DEGs identified current study Among hub genes enriched focal adhesion pathway upstream regulators PTK2 PTK2 key oncogene leading tumour formation progression associated poor survival NSCLC However clinical experiments urgently needed evaluate molecular role PTK2 NSCLC As biomarker NSCLC molecular mechanisms clinical application PTK2 require exploration future studies Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 720 A Cui et al Identification important genes pathways NSCLC COL1A1 MMP1 VWF 12 10 8 6 4 2 0 10 8 6 4 2 0 LUAD numT 483 numN 347 LUSC numT 486 numN 338 LUAD numT 483 numN 347 LUSC numT 486 numN 338 LUAD numT 483 numN 347 LUSC numT 486 numN 338 ADAM12 CD36 OGN LUAD numT 483 numN 347 LUSC numT 486 numN 338 EDN1 12 10 8 6 4 2 0 8 6 4 2 0 8 6 4 2 0 LUAD numT 483 numN 347 LUSC numT 486 numN 338 LUAD numT 483 numN 347 LUSC numT 486 numN 338 CTHRC1 CAV1 10 8 6 4 2 0 LUAD numT 483 numN 347 LUSC numT 486 numN 338 LUAD numT 483 numN 347 LUSC numT 486 numN 338 LUAD numT 483 numN 347 LUSC numT 486 numN 338 ITGA8 14 12 10 8 6 4 2 0 6 5 4 3 2 1 0 8 6 4 2 0 6 4 2 0 LUAD numT 483 numN 347 LUSC numT 486 numN 338 Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 Translational Cancer Research Vol 11 No 4 April 2022 721 COL1A1 202311_s_at MMP1 204475_at VWF 202112_at HR 152 132175 logrank P5e09 B y t l b b o r P 10 08 06 04 02 00 Expression Low High 0 50 100 150 200 Number risk Low High 666 1259 323 504 Time months 69 134 14 43 2 5 y t l b b o r P 10 08 06 04 02 00 Expression Low High 0 50 HR 116 1135 logrank P0047 100 Time months 150 200 y t l b b o r P 10 08 06 04 02 00 Expression Low High 0 50 HR 062 052073 logrank P54e09 100 Time months 150 200 Number risk Low High 1425 500 235 592 51 152 8 49 0 7 Number risk Low High 1421 504 586 241 166 37 52 5 6 1 ADAM12 204943_at CD36 206488_s_at OGN 222722_at y t l b b o r P 10 08 06 04 02 00 Expression Low High HR 131 115149 logrank P53e05 y t l b b o r P 10 08 06 04 02 00 Expression Low High HR 087 076099 logrank P0038 0 50 100 150 200 0 50 100 150 200 Number risk Low High 1178 747 575 252 Time months 154 49 50 7 7 0 Number risk 1263 Low High 662 534 293 Time months 130 73 41 16 6 1 y t l b b o r P 10 08 06 04 02 00 Expression Low High 0 50 Number risk Low High 837 307 366 179 HR 047 038059 logrank P11e11 100 Time months 150 101 38 39 7 200 4 2 EDN1 222802_at CTHRC1 225681_at CAV1 212097_at 10 08 06 04 02 00 y t l b b o r P Expression Low High HR 066 056079 logrank P26e06 10 08 06 04 02 00 y t l b b o r P Expression Low High HR 128 106154 logrank P001 0 50 100 150 200 Number risk Low 641 High 503 291 254 Time months 86 53 27 9 5 1 ITGA8 235666_at 0 50 100 150 200 Number risk 345 Low 799 High 167 378 Time months 41 98 10 36 2 4 10 08 06 04 02 00 y t l b b o r P Expression Low High 0 50 Number risk Low 865 High 1060 310 517 HR 069 06078 logrank P4e09 100 150 Time months 82 121 21 36 200 2 5 HR 048 041057 logrank P1E16 10 08 06 04 02 00 y t l b b o r P Expression Low High 0 50 100 150 200 Time months Number risk Low High 354 790 135 410 43 96 22 24 3 3 Figure 4 The expression survival prognosis 10 hub genes NSCLC A Compared normal specimens genes upregulated genes downregulated NSCLC specimens P005 B KaplanMeier plotter analyse survival rate 10 hub genes Seven 10 hub genes correlated survival prognosis NSCLC P001 P005 LUAD lung adenocarcinoma LUSC lung squamous cell carcinoma NSCLC nonsmall cell lung cancer Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 722 Cui et al Identification important genes pathways NSCLC Table 5 KEGG pathway analysis hub genes NSCLC Pathway ID hsa04510 hsa04512 hsa04151 Name Count Focal adhesion ECMreceptor interaction PI3KAkt signaling pathway 4 3 3 5714 4286 4286 P value Genes 104E04 VWF CAV1 ITGA8 COL1A1 933E04 001407 VWF ITGA8 COL1A1 VWF ITGA8 COL1A1 KEGG Kyoto Encyclopedia Genes Genomes NSCLC nonsmall cell lung cancer A n o l l l m r e p t p r c s n r T 150 125 100 75 50 25 0 D 10 08 06 04 y t l b b o r P Expression PTK2 LUAD based sample types Expression PTK2 LUSC based sample types B n o l l l m r e p t p r c s n r T 150 125 100 75 50 25 0 Normal n59 Primary tumor n515 Normal n52 Primary tumor n503 TCGA samples PTK2 LUSC HR 143 106193 logrank P0019 C 10 08 06 04 y t l b b o r P TCGA samples PTK2 LUAD HR 069 048101 logrank P0056 02 Expression Low High 00 02 Expression Low High 00 0 10 20 30 Time months 40 50 60 0 10 20 30 Time months 40 50 60 Number risk Low 223 272 170 207 129 140 93 103 67 64 53 52 44 41 High Number risk Low 377 127 310 103 213 71 121 46 80 28 49 23 27 15 High Figure 5 Expression survival prognosis PTK2 NSCLC AB PTK2 significantly upregulated LUAD LUSC P001 C PTK2 associated worse survival rate LUSC P005 D PTK2 correlated survival prognosis LUAD P005 P001 LUAD lung adenocarcinoma LUSC lung squamous cell carcinoma NSCLC nonsmall cell lung cancer Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 Translational Cancer Research Vol 11 No 4 April 2022 723 Acknowledgments We like thank PhD Lijia Xiao help polishing article Funding This study funded Science Technology Planning Project Shenzhen No JCYJ20140415151845365 Basic Medical Health Research Project Baoan District No 2020JD428 Footnote Reporting Checklist The authors completed REMARK reporting checklist Available httpstcr amegroupscomarticleview1021037tcr211986rc Data Sharing Statement Available httpstcramegroups comarticleview1021037tcr211986dss Conflicts Interest All authors completed ICMJE uniform disclosure form available httpstcramegroups comarticleview1021037tcr211986coif The authors conflicts declare Ethical Statement The authors accountable aspects work ensuring questions related accuracy integrity work appropriately investigated resolved All procedures performed study involving human participants accordance Declaration Helsinki revised 2013 Open Access Statement This Open Access article distributed accordance Creative Commons AttributionNonCommercialNoDerivs 40 International License CC BYNCND 40 permits non commercial replication distribution article strict proviso changes edits original work properly cited including links formal publication relevant DOI license See httpscreativecommonsorglicensesbyncnd40 References 1 Jemal A Bray F Center MM et al Global cancer statistics CA Cancer J Clin 2011616990 Erratum CA Cancer J Clin 201161134 2 Govindan R Page N Morgensztern D et al Changing epidemiology smallcell lung cancer United 3 States 30 years analysis surveillance epidemiologic end results database J Clin Oncol 200624453944 Imyanitov EN Iyevleva AG Levchenko EV Molecular testing targeted therapy nonsmall cell lung cancer current status perspectives Crit Rev Oncol Hematol 2021157103194 4 Friedlaender A Addeo A Russo A et al Targeted therapies early stage NSCLC hype hope Int J Mol Sci 2020216329 5 Vansteenkiste J Crinò L Dooms C et al 2nd ESMO consensus conference lung cancer earlystage non smallcell lung cancer consensus diagnosis treatment followup Ann Oncol 201425146274 6 Tsao AS Scagliotti GV Bunn PA Jr et al Scientific advances lung cancer 2015 J Thorac Oncol 20161161338 7 Hirsch FR Scagliotti GV Mulshine JL et al Lung cancer current therapies new targeted treatments Lancet 2017389299311 8 Fu Q Yang F Zhao J et al Bioinformatical identification key pathways genes human hepatocellular carcinoma CSN5 depletion Cell Signal 2018497986 9 Gong L Zhang D Dong Y et al Integrated bioinformatics analysis identificating therapeutic targets aspirin small cell lung cancer J Biomed Inform 201888208 10 Davis S Meltzer PS GEOquery bridge gene expression omnibus GEO BioConductor Bioinformatics 20072318467 11 Ashburner M Ball CA Blake JA et al Gene ontology tool unification biology The gene ontology consortium Nat Genet 200025259 12 Kanehisa M Furumichi M Tanabe M et al KEGG new perspectives genomes pathways diseases drugs Nucleic Acids Res 201745D35361 13 Jiao X Sherman BT Huang da W et al DAVIDWS stateful web service facilitate geneprotein list analysis Bioinformatics 20122818056 14 Szklarczyk D Gable AL Lyon D et al STRING v11 proteinprotein association networks increased coverage supporting functional discovery genome wide experimental datasets Nucleic Acids Res 201947D60713 15 Shannon P Markiel A Ozier O et al Cytoscape software environment integrated models biomolecular interaction networks Genome Res Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986 724 2003132498504 16 Tang Z Li C Kang B et al GEPIA web server cancer normal gene expression profiling interactive analyses Nucleic Acids Res 201745W98W102 17 Győrffy B Survival analysis entire transcriptome identifies biomarkers highest prognostic power breast cancer Comput Struct Biotechnol J 20211941019 18 Chandrashekar DS Bashel B Balasubramanya SAH et al UALCAN portal facilitating tumor subgroup gene expression survival analyses Neoplasia 20171964958 19 Siegel RL Miller KD Fuchs HE et al Cancer statistics 2021 CA Cancer J Clin 202171733 Cui et al Identification important genes pathways NSCLC 29 Gómez Del Pulgar T Cebrián A FernándezAceñero MJ et al Focal adhesion kinase predictor tumour response risk factor recurrence neoadjuvant chemoradiation rectal cancer J Cell Mol Med 201620172936 30 Li M Hong LI Liao M et al Expression clinical significance focal adhesion kinase adrenomedullin epithelial ovarian cancer Oncol Lett 20151010037 31 Hsu NY Chen CY Hsu CP et al Prognostic significance expression nm23H1 focal adhesion kinase nonsmall cell lung cancer Oncol Rep 200718815 32 Wang C Yang R Yue D et al Expression FAK PTEN bronchioloalveolar carcinoma lung adenocarcinoma Lung 20091871049 20 Queiroz RM Madan R Chien J et al Changes 33 Zhang H Shao H Golubovskaya VM et al Efficacy Olinked Nacetylglucosamine OGlcNAc homeostasis activate p53 pathway ovarian cancer cells J Biol Chem 201629118897914 focal adhesion kinase inhibition nonsmall cell lung cancer oncogenically activated MAPK pathways Br J Cancer 201611520311 21 Hao XL Han F Zhang N et al TC2N novel oncogene accelerates tumor progression suppressing p53 signaling pathway lung cancer Cell Death Differ 201926123550 22 Yan H Guo M Zou J et al Promotive effect Talin1 protein gastric cancer progression PTK2 PXNVCLECadherinCAPN2MAPK1 signaling axis J Clin Lab Anal 202034e23555 23 Batista S Maniati E Reynolds LE et al Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis drive tumour metastasis Nat Commun 201455054 24 Sieg DJ Hauck CR Ilic D et al FAK integrates growth factor integrin signals promote cell migration Nat Cell Biol 2000224956 25 Zhao X Guan JL Focal adhesion kinase signaling pathways cell migration angiogenesis Adv Drug Deliv Rev 2011636105 26 Gu HJ Zhou B Focal adhesion kinase promotes progression predicts poor clinical outcomes patients osteosarcoma Oncol Lett 201815622532 27 Almstedt K Sicking I Battista MJ et al Prognostic significance focal adhesion kinase nodenegative breast cancer Breast Care Basel 20171232933 28 Omura G Ando M Saito Y et al Association upregulated expression focal adhesion kinase poor prognosis tumor dissemination hypopharyngeal cancer Head Neck 20163811649 34 Infante JR Camidge DR Mileshkin LR et al Safety pharmacokinetic pharmacodynamic phase I dose escalation trial PF00562271 inhibitor focal adhesion kinase advanced solid tumors J Clin Oncol 201230152733 35 Jones SF Siu LL Bendell JC et al A phase I study VS 6063 secondgeneration focal adhesion kinase inhibitor patients advanced solid tumors Invest New Drugs 20153311007 36 Shimizu T Fukuoka K Takeda M et al A firstinAsian phase 1 study evaluate safety pharmacokinetics clinical activity VS6063 focal adhesion kinase FAK inhibitor Japanese patients advanced solid tumors Cancer Chemother Pharmacol 2016779971003 37 Constanzo JD Tang KJ Rindhe S et al PIAS1FAK interaction promotes survival progression non small cell lung cancer Neoplasia 20161828293 Erratum Neoplasia 201618457 38 Roberts WG Ung E Whalen P et al Antitumor activity pharmacology selective focal adhesion kinase inhibitor PF562271 Cancer Res 200868193544 Cite article Cui S Lou S Feng J Tang X Xiao X Huang R Guo W Zhou Y Huang F Identification genes pathways leading poor prognosis nonsmall cell lung cancer integrated bioinformatics analysis Transl Cancer Res 2022114710724 doi 1021037tcr211986 Translational Cancer Research All rights reserved Transl Cancer Res 2022114710724 httpsdxdoiorg1021037tcr211986